31314-37-1

Basic information

• Product Name: Piperidine, 1-ethyl-4,4-diphenyl-
• CAS NO: 31314-37-1
• Molecular Formula: C19H23N
• Molecular Weight: 265.398
• Mol File: 31314-37-1.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: Piperidine, 1-ethyl-4,4-diphenyl-(CAS DataBase Reference)
• NIST Chemistry Reference: Piperidine, 1-ethyl-4,4-diphenyl-(31314-37-1)
• EPA Substance Registry System: Piperidine, 1-ethyl-4,4-diphenyl-(31314-37-1)

Safety Data

• Hazardous Substances Data: 31314-37-1(Hazardous Substances Data)

Upstream product

• 74-96-4 ethyl bromide 
• 34273-01-3 4,4-diphenylpiperidine 
• 13721-15-8 3-benzoyl-1-ethyl-4-phenyl-4-hydroxypiperidine 
• 71-43-2 benzene 
• 41661-47-6 piperidin-4-one 
• 10338-69-9 1,2,3,6-tetrahydro-4-phenylpyridine 
• 3612-20-2 1-phenylmethyl-4-piperidone 
• 40105-95-1 4,4-diphenyl-N-benzylpiperidine 
• 40105-98-4 1-Ethoxycarbonyl-4,4-diphenylpiperidin 
• 63843-83-4 1-benzyl-4-hydroxy-4-phenylpiperidine 
• 14554-17-7 N-benzyl-3-benzoyl-4-hydroxy-4-phenylpiperidine 

Relevant articles and documents

Synthesis, physico-chemical properties and pharmacological screening results of budipine and related 1-alkyl-4,4-diphenylpiperidines

1-Alkyl-4,4-diphenylpiperidines are accessible in a simple manner and with attractive yields by regioselective reaction of certain piperidine derivatives, particularly 3-aroyl-4-aryl-4-hydroxypiperidines, which can be varied widely at the nitrogen atom, with benzene under Friedel-Crafts conditions. The physico-chemical parameters, which are important for the transport and the distribution of a drug in a living system, are discussed for the 1-tert-butyl derivative (13) (budipine) (pK(a), partition coefficient P, saturation concentration c(s), surface activity, protein binding). Rapid absorption of this drug in man is indicated by the size of the permeability coefficient P(M) of the passive transport through artificial phospholipid collodium membranes as well as the invasion curves calculated from P(M). According to pharmacological screening tests, most of the compounds of this class show marked antagonistic activity against experimentally generated pathological states in mice (tremorine and reserpine antagonism) which suggest their potential use in the therapy of Parkinson's disease. 13 has been selected for detailed investigations. Structure-activity analyses did not readily demonstrate the presence of a relationship between the type of alkyl substituent at the piperidine nitrogen atom and the pharmacological screening results obtained.

4,4-Diarylpiperidines and process of making the same

4,4-Diarylpiperidine compounds, preferably 4,4-diphenylpiperidine which are substituted or unsubstituted in the 1-position of the piperidine nucleus, such as 1-(lower alkyl)-4,4-diphenylpiperidines, 1-(lower alkyl)-4-phenyl-4-tolylpiperidines, and their s